O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

British Journal of Cancer

Volumn 78, Issue 9, 1998, Pages 1199-1202

  Middleton, M R ^a   Lunn, J M ^b   Morris, C ^a   Rustin, G ^c   Wedge, S R ^d   Brampton, M H ^e   Lind, M J ^b   Lee, S M ^a   Newell, D R ^b   Bleehen, N M ^f   Newlands, E S ^d   Calvert, A H ^b   Margison, G P ^a   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e Kirbymoorside ^*  (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Melanoma; O6 methylguanine DNA methyltransferase; Response; Temozolomide

Indexed keywords

DNA METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DNA REPAIR; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; MELANOMA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING; ADULT; BIOPSY; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOPSY; DACARBAZINE; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 0031597371     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.654     Document Type: Article

References (24)

1. Bleehen N, Newlands E, Lee S, Thatcher N, Selby P, Calvert A, Rustin G, Brampton M and Stevens M (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913
2. Bower M, Newlands E, Bleehen N, Brada M, Begent R, Calvert H, Colquhoun I, Lewis P and Brampton M (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488
3. Branch P, Aquilina G, Bignami M and Karran P (1993) Detective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652-654
4. Catapano C, Broggini M, Erba E, Ponti M, Mariani L, Citti L and D'Incalci M (1987) In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukaemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47: 4884-4889
5. 6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 15: 279-292
6. 6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours. Br J Cancer 71: 37-39
7. Franchi A, Papa G, D'Atri S, Piccioni D, Masi M and Bonmassar E (1992) Cytotoxic effects of dacarbazine in patients with acute myelogenous leukaemia: a pilot study. Haematologica 77: 146-150
8. Griffin S, Branch P, Xu Y and Karran P (1994) DNA mismatch binding and incision at modified guanine hases by extracts of mammalian cells: implications for tolerance to DNA methylation damage. Biochemistry 33: 4787-4793
9. Karran P and Bignami M (1992) Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 20: 2933-2940
10. Kat A, Thilly W, Fang W, Longley M, Li G and Modrich P (1993) An alkylation-tolerant mutator cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424-6428
11. 6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 51: 619-623
12. 6-alkylguanine-DNA-alkytransferase in human liver and melanoma. Br J Cancer 66: 355-360
13. Lee S, Betticher D and Thatcher N (1995) Melanoma: chemotherapy. Br Med Bull 51: 609-630
14. Liu L, Markowitz S and Gerson S (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56: 5375-5379
15. 6-methylguanine-DNA methyltransferase and comparison of detection methods tor the methylated enzyme in polyacrylamide gels and electroblots. Biochem J 277: 89-96
16. Margison G and O'Connor P (1990) Biological consequences of reactions with DNA: role of specific lesions. In Handbook of Experimental Pharmacology, Cooper C and Grover P (eds), pp. 547-571. Springer-Verlag: Berlin
17. Miller A, Hoogstraten B, Staquet M and Berad D (1981). Reporting results of cancer treatment. Cancer 47: 207-214
18. Newlands F, Stevens M, Wedge S, Wheelhouse R and Brock C (1997) Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 23: 35-61
19. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129
20. 6-methylguanine-induced replication blocks. Carcinogenesis 16: 1775-1782
21. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74: 1030-1036
22. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Offset publication number 48. WHO: Geneva
23. 6-methylguanine-DNA methyltransferase activity using oligonucleotides and restriction enzyme in human brain tumours. Int J Oncol 9: 781-786
24. 6-methylguanine as a free hase. Cancer Res 46: 1663-1668